title: Prolonged flare-up of testosterone after administration of a gonadotrophin agonist to a sex offender: an under-recognised risk?
authors: Johan
authors: J
authors: Huygh
authors: Ann
authors: A
authors: Verhaegen
authors: Kris
authors: K
authors: Goethals
authors: Paul
authors: P
authors: Cosyns
authors: Christophe
authors: C
authors: De Block
authors: Luc
authors: L
authors: Van Gaal
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D057237:Criminals; D017373:Cyproterone Acetate / Q000009:adverse effects / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010262:Paraphilic Disorders / Q000097:blood / Q000188:drug therapy*; D011613:Psychotherapy; D012742:Sex Offenses / Q000517:prevention & control*; D013739:Testosterone / Q000097:blood*; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D017373:Cyproterone Acetate